Riding the popularity of drugs targeting vascular endothelial growth factor (VEGF), Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis Group are pushing forward with the VEGF Trap, positioning the product as a chief competitor for Avastin. (BioWord Today)